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Vitamin D has been linked to cancer development in both pre-clinical and epidemiological studies. Our study examines the
association between serum levels of vitamin D and cancer incidence in the Capital Region of Denmark. Individuals who had
vitamin D analyzed at The Copenhagen General Practitioners Laboratory between April 2004 and January 2010 were linked to
Danish registries with end of follow-up date at Dec 31st 2014, excluding individuals with pre-existing cancer. Cox regression
models adjusted for age in one-year intervals, sex, month of sampling, and Charlson Comorbidity Index were applied. The
study population of 217,244 individuals had a median vitamin D level of 46 nmol/L (IQR 27–67 nmol/L). Non-melanoma skin
cancer was the most frequent form of cancer, followed by breast-, lung-, and prostate cancers. No associations were found
between increments of 10 nmol/L vitamin D and incidence of breast, colorectal, urinary, ovary or corpus uteri cancer. However,
higher levels of vitamin D were associated with higher incidence of non-melanoma (HR 1.09 [1.09–1.1]) and melanoma skin
cancer (HR 1.1 [1.08–1.13]) as well as prostate (HR 1.05 [1.03–1.07]) and hematological cancers (HR 1.03 [1.01–1.06]), but
with lower incidence of lung cancer (HR 0.95 [0.93–0.97]). In our study, vitamin D levels are not associated with the incidence
of several major cancer types, but higher levels are signiﬁcantly associated with a higher incidence of skin, prostate, and
hematological cancers as well as a lower incidence of lung cancer. These results do not support an overall protective effect
against cancer by vitamin D.
Introduction
25-hydroxy vitamin D (vitamin D) is a precursor for the ste-
roid hormone calcitriol that besides having a central role in
calcium homeostasis, has shown antineoplastic effects in cellu-
lar and animal studies1. In humans, exposure of the skin to
sunlight largely determines the level of circulating vitamin D
with a smaller contribution from dietary intake. In the past
years, several epidemiological studies and meta-analyses have
examined the association between vitamin D and cancer
reporting inconsistent results2. The incidence of some cancer
types such as colorectal cancer has generally shown inverse
associations with vitamin D3 while for other cancer types such
as prostate cancer, positive associations have been seen4.
Besides the role in calcium homeostasis, one of the biological
functions of vitamin D is involvement in immune modulation.
The active metabolite calcitriol has immune regulatory effects,
mimicking what is seen in the immune regulatory environ-
ment in cancer5. Furthermore, calcitriol can also modulate the
effect of known external carcinogenic substances in some can-
cers, e.g. by counteracting the effects of tobacco smoking on
bronchial epithelium6. However, the effects of calcitriol might
be dependent on the physiological concentration and has a
biphasic effect on cancer cell growth in vitro7.
The Copenhagen General Practitioners Laboratory serviced
general practitioners from the Greater Copenhagen area with
approximately 1.1 million inhabitants (ﬁrst quarter of 2010).
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A database (CopD) included measurements of vitamin D from
this laboratory in the period from 2004 to 2010. A reverse
J-shaped association between serum levels of vitamin D and
all-cause mortality has been reported based on the CopD
database indicating an upper beneﬁcial limit of vitamin D8.
This ﬁnding was corroborated by an analysis of the Third
National Health and Nutrition Examination Survey, NHANES
III9. In Denmark, like in other Western countries, awareness
of the role of vitamin D in general health has increased in
recent years, and a large part of the Danish population takes
dietary vitamin D supplements on a regular basis10. In the
period 2004 to 2010, the amount of vitamin D analyses per-
formed at the Copenhagen General Practitioners Laboratory
grew exponentially, and 14% of all requests for blood sam-
pling included a vitamin D analysis8. Thus, almost one quarter
of the inhabitants had their blood analyzed for vitamin D,
suggesting a broad indication for vitamin D analysis. There-
fore, the CopD database provides a unique opportunity to
assess associations between vitamin D levels and disease out-
comes in a regional population. The aim of the present study
was to test the hypothesis that the level of vitamin D could be
associated with both a lower and a higher incidence of cancer,
depending on the type of cancer examined.
Materials and Methods
Study population
The CopD database included measurements of vitamin D levels
extracted from The Copenhagen General Practitioners Labora-
tory8. The laboratory served all general practitioners in the
Copenhagen Municipality and the former Copenhagen County
in Denmark. The population of the Copenhagen area was pre-
dominantly of Danish descent (83%) or non-Danish European
descent (9%) in 2008 as deﬁned by Statistics Denmark
(Statistics Denmark http://www.statbank.dk/10021, accessed
May 2018).
Our study population comprised 247,574 individuals who
had at least one measurement of serum vitamin D in the
period from April 2004 to January 2010. In the present study,
the ﬁrst measurement of vitamin D from each individual from
the CopD database was linked at individual-level to The Dan-
ish Cancer Registry11, The National Patient Registry12, and
the Danish Civil Registration System13; with date of last
follow-up as of December 31st 2014. We only included the
ﬁrst measurement to exclude bias by possible supplementation
initiated after the ﬁrst measurement. Firstly, we excluded indi-
viduals with replacement social security numbers since they
are temporary until a valid social security number is provided
(N = 716). Then, individuals with a pre-existing cancer diag-
nosis from the Danish Cancer Registry (N = 26,644) at the
time of the ﬁrst vitamin D measurement were excluded.
Thereafter, remaining individuals who had a cancer diagnosis
in the National Patient Registry (N = 2970) at the time of the
ﬁrst vitamin D measurement were excluded to reach a ﬁnal
cohort size of 217,244 individuals.
Analysis of vitamin D
Vitamin D levels were assessed in serum using two different
commercially available assays: LIAISON 25(OH)D assay
(Diasorin, Italy); and OCTEIA 25(OH)D3 and 25(OH)D2
(Immunodiagnostic Systems, UK) quantifying both 25-hydroxy
vitamin D2 and 25-hydroxy vitamin D3 as described in detail
by Durup et al8. Quantitative values less than 10 nmol/L were
set to 10 nmol/L due to the lower limit of the assays.
Confounding variables
Besides age, sex and month of sampling, comorbidity was
assessed by the Charlson Comorbidity Index14,15 using the
International Classiﬁcation of Diseases (ICD-10) codes. The
Charlson Comorbidity Index was included at time of vitamin
D analysis with all available diagnoses registered in the
National Patient Registry since 1977.
Study endpoints
Information about incident cancers was obtained from The
Danish Cancer Registry based on ICD-10 codes and grouped
as shown in Supporting Information Table S1. Non-Hodgkin
lymphoma was examined as a subgroup of hematological can-
cers as well as included in the hematological cancers. Each
type of cancer with number of events above 200 in the follow-
up period was included as outcome variables. Information on
emigration and vital status was obtained from the Danish
Civil Registration System with the date of last follow-up being
December 31st 2014.
Statistical analysis
The association between vitamin D levels and the incidence of
each type of cancer was estimated using a Cox proportional
hazards model with time since ﬁrst vitamin D measurement
as the underlying timescale. All subjects were followed to the
time of ﬁrst cancer (any cancer diagnosis, N = 18,359), time
of emigration (N = 5583), time of death (N = 24,087), or end
of follow-up (by December 31st 2014), whichever came ﬁrst.
What’s new?
In recent years, interest in the role of vitamin D in health has increased, and more blood tests have included vitamin D
analysis. Taking advantage of these data, the authors here investigated the link between vitamin D and cancer incidence in a
large Danish cohort. They found no association between circulating vitamin D and most cancers they studied. Higher levels of
vitamin D did correlate with reduced risk of lung cancer, they found, and also with increased risk of skin cancers, prostate
cancer, non-Hodgkin’s lymphoma, and hematologic cancers.
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The associations were presented as hazard ratios (HRs) with
corresponding 95% conﬁdence interval (Cl) from crude
models as well as from models adjusted for potential con-
founding effects from comorbidity as the Charlson Comorbid-
ity Index, age at blood sampling in one-year intervals, sex,
and month of blood sampling. All potential confounder vari-
ables were included as strata variables to allow for different
underlying hazards in the strata.
The assumption of proportional hazards for the vitamin D
variable in the Cox regression analysis was checked graphi-
cally using Schoenfeld residual plots. To exclude prevalent
cases, we also computed the effects with delayed entry of one
year as well as 5 years. Furthermore, we performed sensitivity
analyses for sex speciﬁc effects and analyses with vitamin D
levels at the lower limit of the assay of 10 nmol/L set to
5 nmol/L. Also, we analyzed individuals with blood samplings
from April 2005 and onwards to exclude bias from measure-
ments performed from April 2004 to April 2005 that were not
the ﬁrst measurement of vitamin D in the individual.
To detect non-linear associations between vitamin D levels
and the incidence of cancer, we ﬁtted associations of vitamin D
levels and incidence of cancer for each cancer type using
restricted cubic splines with 4 knots placed at 12.5, 25, 75, and
100 nmol/L vitamin D, using 50 nmol/L as the reference. The
lower knots were derived from the cut-offs used in clinical prac-
tice in Europe16. Graphical presentations of estimates together
with 95% pointwise Cl for all cancer types were reviewed but only
those that had signiﬁcant ﬁndings by Cox regression analysis
were displayed as ﬁgures. Since the study was register based there
were nomissing data or loss to follow-up.
The statistical analyses were performed in the SAS 9.3 soft-
ware (SAS institute, Cary, USA). Descriptive analyses of quan-
titative variables were reported as medians with interquartile
ranges (IQR), and the categorical variables as numbers and
percentages of total (%). All HRs were computed with 95%
Cl. P-values were two-sided and considered statistically signif-
icant if less than 0.05.
Results
The study population of 217,244 individuals had a median level
of vitamin D of 46 nmol/L (IQR 27–67 nmol/L), a median age of
48.8 years (IQR 33.5–64.1 years), female predominance (65.3%),
and a low comorbidity burden (Charlson Comorbidity Index of
0 in 79.5%) with pulmonary disease being the most frequent
comorbidity. Vitamin D levels were grouped by clinical cut-offs
into severe deﬁciency (<12.5 nmol/L), moderate deﬁciency
(12.5–25 nmol/L), insufﬁciency (25–50 nmol/L), sufﬁciency
(50–75 nmol/L), moderately high levels (75–100 nmol/L), high
levels (100–125 nmol/L), and very high levels (≥125 nmol/L) for
tabulation of baseline characteristics by the level of vitamin D
(Table 1).
A total of 18,359 individuals were diagnosed with an inci-
dent cancer (8.5% of the population) during the follow-up
period. Non-melanoma skin cancer (N = 5045) was the most
frequent incident cancer followed by breast cancer (N = 2167),
lung cancer (N = 1707), prostate cancer (N = 1470), and colon-
rectosigmoidal cancers (N = 1108). The median level of vitamin
D differed depending on cancer type ranging from 47 nmol/L
in individuals developing an incident lung or rectum cancer to
58 nmol/L in individuals developing a non-melanoma skin can-
cer (Table 2).
In the unadjusted Cox regression analysis, increments of
10 nmol/L in the level of vitamin D were signiﬁcantly posi-
tively associated with almost all incident cancer types
(Table 2). However, when adjusting for the potential con-
founding variables, no associations were found for breast-,
urinary-, colon-rectosigmoidal-, rectum-, ovary, corpus uteri
or cancers of the central nervous system. However, non-
melanoma (HR 1.09 [1.09–1.1]) and melanoma skin cancer
(HR 1.1 [1.08–1.13]), as well as prostate (HR 1.05 [1.03–1.07])
and hematological cancers (HR 1.03 [1.01–1.06]) retained a
signiﬁcant positive association with vitamin D levels, while
lung cancer showed a negative association (HR 0.95
[0.93–0.97]) (Table 2). Applying delayed entry of one year or
ﬁve years produced similar results (Fig. 1, Table 3). For mela-
noma skin cancer, the hazard ratio seemed to peak around a
vitamin D level of 80 nmol/L (Fig. 2a) while it further
increased for non-melanoma skin cancer (Fig. 2b). For indi-
viduals with an incident prostate cancer, the rate of increase
in hazard ratio was largest below a vitamin D level of
80 nmol/L (Fig. 3a) in contrast to individuals with incident
hematological cancers or incident non-Hodgkin lymphomas
where the largest rate of increase in hazard ratio was seen at
the level above 80 nmol/L and 100 nmol/L, respectively
(Figs. 3b and 3c). Finally, for individuals with an incident lung
cancer, the strongest association was for vitamin D levels
below 30 nmol/L (Fig. 3c). The sensitivity analyses yielded no
differences when examining the effect of sex, except for non-
Hodgkin lymphoma, where the association was only signiﬁ-
cant in women (Table S2); when only examining individuals
who had their blood analyzed for vitamin D from April 2005
and onwards (Table S3-4); nor when calculating with the
lower limit of vitamin D set to 5 nmol/L (data not shown).
Discussion
We examined associations between the level of vitamin D and
the incidence of several cancer types in a large population
from general practice in Denmark. We found that the level of
vitamin D showed no association with most cancer types,
while in some cancer types, higher levels of vitamin D were
associated with both higher and lower incidence of cancer
depending on the type of cancer examined.
The CopD study was observational and thus we could not
examine causality due to possible residual confounding and
reverse causation. Furthermore, a general problem of observa-
tional cohort studies is that participants tend to be healthier
than their source population. The opposite could be an issue
for the present study since the request for vitamin D analysis,
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and thereby the study participants, was selected by general
practitioners. The generalizability to the entire population
may therefore be a concern. However, in 2010 the background
population serviced by the Copenhagen General Practitioners
Laboratory was comprised of approximately 1.1 million peo-
ple and almost one quarter thereof had vitamin D assessed in
the period from 2004 to 2010, enhancing the likelihood of
generalizability of our study. The cancer incidence of the
CopD study population was higher than expected. We
observed 18,359 incident cancer diagnoses, whereas an age-
and sex-standardized calculation based on the cancer inci-
dence rates for the period 2004 to 2014 in the entire Danish
population revealed an expected number of 11,733 (5.4%).
The major difference was seen for non-melanoma skin cancer
with 5045 cancers observed vs. 643 expected. This was even
more clear if calculated with delayed entry of 5 years where
there was a total of 3664 observed cancers vs. 2698 expected
and the numbers for non-melanoma skin cancer were 1062
observed cancers vs. 145 expected. This points to, that the
CopD population may be more closely followed in the health
Figure 1. Forest plot showing association with cancer incidence per 10 nmol/L increments of 25-hydroxy vitamin D. Hazard ratios (HR) are
presented with 95% conﬁdence intervals (Cl). Analyses are performed with delayed entry of 1 year.
Table 2. Results from cox regression analysis
Cases
25-hydroxy vitaminD,
nmol/L Unadjusted Adjusted1
Cancer N Median (IQR) HR 95% Cl p HR 95% Cl p
Non-melanoma skin cancer 5,045 58 (40–78) 1.11 1.10–1.12 <0.0001 1.09 1.09–1.10 <0.0001
Breast 2,167 51 (33–70) 1.05 1.03–1.06 <0.0001 1.00 0.99–1.02 0.6
Lung 1,707 47 (28–66) 1.00 0.98–1.01 0.8 0.95 0.93–0.97 <0.0001
Prostate 1,470 51 (35–70) 1.05 1.03–1.07 <0.0001 1.05 1.03–1.07 <0.0001
Colon-rectosigmoidal 1,108 49 (32–69) 1.03 1.01–1.05 0.0004 0.98 0.96–1.00 0.1
Urinary 1,016 48 (30–66) 1.02 1.00–1.04 0.2 0.99 0.96–1.01 0.3
Hematological 968 53 (32–74) 1.06 1.04–1.08 <0.0001 1.03 1.01–1.06 0.004
Non-Hodgkin lymphoma 425 53 (31–73) 1.03 0.99–1.06 0.1 1.03 1.00–1.07 0.07
Central nervous system 689 49 (31–69) 1.03 1.00–1.05 0.03 1.00 0.98–1.03 0.8
Melanoma of the skin 684 57 (41–75) 1.10 1.08–1.13 <0.0001 1.10 1.08–1.13 <0.0001
Rectum 461 47 (32–67) 1.01 0.98–1.04 0.6 0.98 0.94–1.01 0.2
Corpus-uteri 347 52 (33–69) 1.04 1.01–1.08 0.01 0.99 0.96–1.03 0.7
Ovary, fallopian tube and broad ligament 254 52 (34–69) 1.05 1.01–1.09 0.01 0.99 0.94–1.03 0.6
Abbreviations: IQR, Interquartile range; Cl, confidence intervals. Incident cancers, 25-hydroxy vitamin D levels, and hazard ratios (HR)from both unad-
justed and adjusted cox regression analysis per 10 nmol/L increments in 25-hydroxy vitamin D.
1Adjusted for age in 1-year intervals, sex, month of sampling, and comorbidity.
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system compared to the general population. Another concern
is the skewed sex distribution with an overweight of women,
especially in the groups with high levels of vitamin D, reﬂect-
ing the well-known higher frequency of health concern in
women. This could be the reason for the higher numbers of
non-Hodgkin lymphomas in women found in our study com-
pared to what is seen in the general population where these
diseases have male predominance. As revealed in the sensitiv-
ity analysis, the association of non-Hodgkin lymphoma with
vitamin D was only signiﬁcant in women. However, the asso-
ciations in men and women were not signiﬁcantly different by
interaction analysis.
Since the study was register based, we had complete follow-up
but no available information on smoking habits, alcohol con-
sumption, obesity or exercise. Confounding by these factors can
therefore neither be evaluated nor ruled out. Inclusion of the
Charlson Comorbidity Index14 was done to account for diseases
that arise from these exposures. Outcomes (cancer incidence,
emigrations, and overall mortality) were obtained by registry
linkage. The Danish Cancer Registry and The Danish Civil Regis-
tration system both have very high validity, and the risk of mis-
classiﬁcation is considered minimal. Misclassiﬁcation could be of
greater concern as to the vitamin D exposure assessment. We
only included one sampling per participant and the assays used
are known to have some variability. However, all measurements
were performed at the same laboratory with well documented
and internationally approved quality assured assays to reduce this
variability8. The potential errors related to vitamin D assessment
would most likely be non-differential and thereby lead to an
underestimation of the associations.
Several other studies, both separate studies and meta-ana-
lyses, have examined the association between vitamin D and
cancer incidence2,17. Like the present study, Skaaby et al.
showed a signiﬁcantly higher incidence of non-melanoma skin
cancers with higher levels of vitamin D in approximately
12,000 individuals pooled from 3 population based studies
Table 3. Results from analyses performed with delayed entry of 5 years
Delayed entry 5 years N HR 95% CI p
Non-melanoma skin cancer 1,062 1.11 1.09–1.13 <0.0001
Breast 455 1.02 0.99–1.05 0.2
Lung 318 0.93 0.89–0.98 0.003
Prostate 221 1.09 1.04–1.15 0.0002
Colon-rectosigmoidal 222 0.97 0.93–1.03 0.3
Urinary 213 0.98 0.93–1.04 0.5
Hematological 181 1.08 1.03–1.13 0.002
Non-Hodgkin lymphoma 84 1.10 1.03–1.17 0.006
Central nervous system 144 1.00 0.95–1.06 0.9
Melanoma of the skin 130 1.14 1.08–1.20 <0.0001
Rectum 88 0.98 0.91–1.06 0.7
Corpus-uteri 90 0.99 0.92–1.06 0.7
Ovary, fallopian tube and broad ligament 53 0.98 0.89–1.08 0.7
Abbreviation: Cl, confidence intervals. Incident cancers, 25-hydroxy vitamin D levels, and hazard ratios (HR) from adjusted1 cox regression analysis per
10 nmol/L increments in 25-hydroxy vitamin D.
1Adjusted for age in 1 year intervals, sex, month of sampling, and comorbidity.
Figure 2. Restricted cubic spline curves for incident skin cancers by the level of 25-hydroxy vitamin D. Hazard ratios (HR) are presented with
95% pointwise conﬁdence intervals (Cl). Analyses are performed with delayed entry of 1 year. (a) Melanoma. (b) Non-melanoma.
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carried out in Denmark from 1993 to 200818. Thus, it is likely
there is confounding by sun exposure for non-melanoma skin
cancer as these cancers are induced by exposure of the skin to
the ultraviolet light from the sun19. Furthermore, an inverse
association of vitamin D levels with lung cancer was shown by
Afzal et al. in more than 9000 individuals from The Copenha-
gen City Heart Study20. Of note, their ﬁndings were unaf-
fected by smoking habits.
For several cancer types, we did not ﬁnd any association
with the level of vitamin D, in contrast to other studies. For
example, a recent meta-analysis performed in the elderly com-
piled from several population based cohorts in Europe showed
an association of higher risk of breast cancer with higher vita-
min D levels21. However, individuals in the CopD study
cohort were younger, and therefore the results are not directly
comparable. Also, a large case–control study based on pooling
of 17 cohorts showed a protective effect of higher vitamin D
levels with regards to the risk of colon-rectosigmoidal cancers
in women22. We do not ﬁnd incident colon-rectosigmoidal
cancers to be associated with the level of vitamin D, neither in
women only. In that respect confounding needs to be consid-
ered. Information on important lifestyle risk factors as smok-
ing, obesity, unhealthy diet and physical inactivity were not
available in the current study and confounding by these
factors are thereby possible. However, these factors are most
often found related to lower blood levels of vitamin D23,24. It
is therefore more likely that adjustment for these factors
would lead to the opposite ﬁnding in our study, i.e. that
higher levels of vitamin D were associated with higher inci-
dence of colon-rectosigmoidal cancers. Also, recent data from
a randomized calcium and vitamin D supplementation trial
suggested that supplementation increased the risk of subse-
quent serrated polyps of the colon, but as a late effect25. We
do not have information on the intake of calcium or vitamin
D supplements in our study, but in Denmark, there is gener-
ally a high consumption of supplements in the Danish popu-
lation (60% of females and 51% of males aged 18 to 75 years)
with a relatively low median level of dietary intake of
7.8–8.4 μg for users of dietary supplements vs. 2.0–2.9 μg in
non-users10. Furthermore, recent studies have examined vita-
min D receptor polymorphisms and risk of colorectal diseases
and found different results for different disease entities26, and
a large Mendelian randomization study provides no evidence
for a causal relationship between vitamin D and risk of colo-
rectal cancers, although small effect sizes and non-linear
relationships cannot be ruled out27. Like our study, none of
these studies had information on potential confounding fac-
tors such as smoking habits, alcohol consumption, body
Figure 3. Restricted cubic spline curves for incident cancers by the level of 25-hydroxy vitamin D. Hazard ratios (HR) are presented with 95%
pointwise conﬁdence intervals (Cl). Analyses are performed with delayed entry of 1 year. (a) Prostate cancer. (b) Hematological cancer. (c)
Non-Hodgkin lymphoma. (d) Lung cancer.
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fatness, physical activity or family history of cancer. Thus, the
possible association between vitamin D levels and colorectal
cancers warrants further large studies including information
on potential confounders and genetic susceptibility as well as
more speciﬁc disease entities as outcome.
For prostate cancer, Schenk et al showed no association of
vitamin D levels with total prostate cancer risk in a nested
case control study of 1700 cases and controls from the Pros-
tate Cancer Prevention Trial28. However, when accounting for
Gleason score, there was a modest increase in the risk of pros-
tate cancer with a Gleason score of 2–6, with increasing vita-
min D levels, but a decrease in risk of prostate cancer with a
Gleason score 8–10. Thus, our results could be biased by a
predominance of low Gleason score groups identiﬁed through
screening using Prostate Speciﬁc Antigen. In Denmark, the
incidence of prostate cancer rose by 2.5-fold in the late 1990’s,
largely due to an increase in the diagnosis of locally advanced
prostate cancers29. In parallel to our results, a large Norwegian
population based nested case control study showed a positive
association between a 30 nmol/L increase in the vitamin D
level and the risk of prostate cancer, not depending on the
stage of the disease at diagnosis30. However, staging was not
done by Gleason score in their study.
The positive association between higher vitamin D levels
and the incidence of non-Hodgkin lymphomas is corrobo-
rated by a recent meta-analysis in ﬁnding no protective effect
of higher vitamin D levels in relation to the risk of developing
non-Hodgkin lymphoma31. Several cancers are associated with
immune suppression, and non-Hodgkin lymphomas occur
more often in patients with non-melanoma skin cancer32. This
mutual association with immune suppression could explain
that we ﬁnd both types of cancers to be positively associated
with the level of vitamin D.
For both skin cancers as well as for prostate and hemato-
logical cancers, and especially non-Hodgkin lymphomas we
found that higher levels of vitamin D were associated with
higher incidence, while we found an inverse association with
lung cancer. The active metabolite of vitamin D, calcitriol, has
several effects on both cancer cells and immune cells and can
also mediate the effects of tobacco carcinogens6. Moreover,
UV-radiation can affect CD4+ T-cells toward a more immune
suppressive environment33. Thus, it is possible that the blood
level of vitamin D could be related to the evolution and pro-
gression of cancer. However, it is also likely that vitamin D is
a surrogate marker for the function of the immune system at
the individual level. This might explain why studies conducted
in cohorts from countries at different latitudes ﬁnd differences
in ‘optimal’ levels of vitamin D such as studies conducted
in the USA vs. in countries from northern Europe34. These
hypotheses remain to be tested.
To conclude, vitamin D levels are not associated with the
incidence of several major cancers such as breast, urinary, and
colon-rectosigmoidal cancers in a population from primary
care in Denmark, but higher vitamin D levels are associated
with a higher incidence of skin, prostate, hematological can-
cers, and non-Hodgkin lymphomas solely as well as a lower
incidence of lung cancer. These results should be interpreted
in the light of the representativeness of the cohort as well as
the known limitation of registry studies in lack of information
on potential confounding factors. Our study results do
not support an overall protective effect against cancer by
vitamin D.
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